Skip to main content
SpringerLink
Log in

Oncological Monitoring of NonMuscle Invasive Bladder Cancer (NMIBC)

  • Chapter
  • First Online:
Bladder Cancer

  • 1051 Accesses

Abstract

Bladder cancer is the most common urinary tract malignancy and the fifth leading new cancer diagnosis in the United States. Nonmuscle-invasive bladder cancer (NMIBC) comprises the majority of these cases and is known for its varying oncological outcomes and need for frequent follow-up and treatment. However, there is significant heterogeneity between surveillance protocols and an undefined role for the implementation of new endoscopic technology and urinary markers. This chapter will serve as a comprehensive and practical guide for the oncological monitoring of NMIBC. Additionally, it will incorporate tips and tricks utilized by experts in the field that can be applied in a urologist’s daily practice.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. National Cancer Institute. Surveillance, epidemiology and ERP. Bladder Cancer – Cancer Stat Facts [Internet]. 2019 [cited 2019 Feb 14]. Available from: https://seer.cancer.gov/statfacts/html/urinb.html.

  2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin [Internet]. 2013 [cited 2019 Feb 14];63(1):11–30. Available from: http://doi.wiley.com/10.3322/caac.21166.

  3. Sylvester RJ, van der Meijden APM, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol [Internet]. 2006 [cited 2019 Feb 12];49(3):466–77. Available from: https://www.sciencedirect.com/science/article/pii/S0302283805008523.

  4. Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, et al. Diagnosis and treatment of non-muscle-invasive bladder cancer: AUA/SUO guideline. J Urol [Internet]. 2016 [cited 2019 Jan 31];196(4):1021–9. Available from: https://www.sciencedirect.com/science/article/pii/S0022534716306292.

  5. Mariappan P, Smith G, Lamb ADG, Grigor KM, Tolley DA. Pattern of recurrence changes in noninvasive bladder tumors observed during 2 decades. J Urol [Internet]. 2007 [cited 2019 Feb 14];177(3):867–75. Available from: https://www.sciencedirect.com/science/article/pii/S0022534706027522.

  6. Mariappan P, Smith G. A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database. J Urol [Internet]. 2005 [cited 2019 Feb 14];173(4):1108–11. Available from: https://www.sciencedirect.com/science/article/pii/S0022534705610117.

  7. Sylvester RJ, Oosterlinck W, van der Meijden APM. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage ta t1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol [Internet]. 2004 [cited 2019 Feb 14];171(6):2186–90. Available from: https://www.sciencedirect.com/science/article/pii/S0022534705621271.

  8. Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BWG, Compérat E, et al. EAU guidelines on non–muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol [Internet]. 2013 [cited 2019 Feb 6];64(4):639–53. Available from: https://www.sciencedirect.com/science/article/pii/S0302283813006015.

  9. Millán-rodríguez F, Chéchile-toniolo G, Salvador-bayarri J, Huguet-pérez J, Vicente-rodríguez J. Upper urinary tract tumors after primary superficial bladder tumors: prognostic factors and risk groups. J Urol [Internet]. 2000 [cited 2019 Feb 15];164(4):1183–7. Available from: https://www.sciencedirect.com/science/article/pii/S0022534705671376.

  10. Holmäng S, Ströck V. Should follow-up cystoscopy in bacillus calmette-guérin–treated patients continue after five tumour-free years? Eur Urol [Internet]. 2012 [cited 2019 Feb 15];61(3):503–7. Available from: https://www.sciencedirect.com/science/article/pii/S0302283811012504.

  11. Soukup V, Babjuk M, Bellmunt J, Dalbagni G, Giannarini G, Hakenberg OW, et al. Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature. Eur Urol [Internet]. 2012 [cited 2019 Feb 15];62(2):290–302. Available from: https://www.sciencedirect.com/science/article/pii/S0302283812005428.

  12. Aaronson DS, Walsh TJ, Smith JF, Davies BJ, Hsieh MH, Konety BR. Meta-analysis: does lidocaine gel before flexible cystoscopy provide pain relief? BJU Int [Internet]. 2009 [cited 2019 Feb 12];104(4):506–10. Available from: http://doi.wiley.com/10.1111/j.1464-410X.2009.08417.x.

  13. Gunendran T, Briggs RH, Wemyss-Holden GD, Neilson D. Does increasing hydrostatic pressure (“Bag Squeeze”) during flexible cystoscopy improve patient comfort: a randomized, controlled study. Urology [Internet]. 2008 [cited 2019 Feb 18];72(2):255–8. Available from: https://www.sciencedirect.com/science/article/pii/S0090429508004652?via%3Dihub.

  14. Patel AR, Jones JS, Babineau D. Lidocaine 2% gel versus plain lubricating gel for pain reduction during flexible cystoscopy: a meta-analysis of prospective, randomized, controlled trials. J Urol [Internet]. 2008 [cited 2019 Feb 24];179(3):986–90. Available from: https://www.sciencedirect.com/science/article/pii/S0022534707028406.

  15. Goel R, Aron M. Cooled lignocaine gel: does it reduce urethral discomfort during instillation? Int Urol Nephrol [Internet]. 2003 [cited 2019 Feb 24];35(3):375–7. Available from: http://link.springer.com/10.1023/B:UROL.0000022910.28815.30.

  16. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics [Internet]. 2003 [cited 2018 Oct 17];21(18):1315–30. Available from.: http://www.ncbi.nlm.nih.gov/pubmed/14750899.

  17. Jichlinski P, Leisinger H-J. Fluorescence cystoscopy in the management of bladder cancer: a help for the urologist! Urol Int [Internet]. 2005 [cited 2019 Feb 12];74(2):97–101. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15756058.

  18. Hungerhuber E, Stepp H, Kriegmair M, Stief C, Hofstetter A, Hartmann A, et al. Seven years’ experience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder. Urology [Internet]. 2007 [cited 2019 Feb 18];69(2):260–4. Available from: https://www.sciencedirect.com/science/article/pii/S0090429506023521.

  19. Zaak D, Hungerhuber E, Schneede P, Stepp H, Frimberger D, Corvin S, et al. Role of 5-aminolevulinic acid in the detection of urothelial premalignant lesions. Cancer [Internet]. 2002 [cited 2019 Feb 18];95(6):1234–8. Available from: http://doi.wiley.com/10.1002/cncr.10821.

  20. Schmidbauer J, Witjes F, Schmeller N, Donat R, Susani M, Marberger M. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol [Internet]. 2004 Jan [cited 2019 Feb 18];171(1):135–8. Available from: http://www.jurology.com/doi/10.1097/01.ju.0000100480.70769.0e.

  21. Daniltchenko DI, Riedl CR, Sachs MD, Koenig F, Daha KL, Pflueger H, et al. Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study. J Urol [Internet]. 2005 [cited 2019 Feb 18];174(6):2129–33. Available from: http://www.jurology.com/doi/10.1097/01.ju.0000181814.73466.14.

  22. Daneshmand S, Schuckman AK, Bochner BH, Cookson MS, Downs TM, Gomella LG, et al. Hexaminolevulinate blue light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA. Nat Rev Urol [Internet]. 2014 [cited 2019 Feb 12];11(10):589–96. Available from: http://www.nature.com/articles/nrurol.2014.245.

  23. Kausch I, Sommerauer M, Montorsi F, Stenzl A, Jacqmin D, Jichlinski P, et al. Collaborative review-bladder cancer photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. Eur Urol [Internet]. [cited 2019 Feb 12];57:595–606. Available from: https://ac.els-cdn.com/S0302283809012032/1-s2.0-S0302283809012032-main.pdf?_tid=af913e72-5713-4ec6-9357-0cf02b9a10cf&acdnat=1550003007_75625e798e66148c2117d7de2382ed23.

  24. Mark JR, Gelpi-Hammerschmidt F, Trabulsi EJ, Gomella LG. Blue light cystoscopy for detection and treatment of non-muscle-invasive bladder cancer. Can J Urol [Internet]. 2012 [cited 2019 Feb 18];19(2):6227–31. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22512972.

  25. Witjes JA, Redorta JP, Jacqmin D, Sofras F, Malmström P-U, Riedl C, et al. Hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non–muscle-invasive bladder cancer: review of the evidence and recommendations. Eur Urol [Internet]. 2010 [cited 2019 Feb 6];57(4):607–14. Available from: https://www.sciencedirect.com/science/article/pii/S0302283810000369.

  26. Gravas S, Efstathiou K, Zachos I, Melekos MD, Tzortzis V. Is there a learning curve for photodynamic diagnosis of bladder cancer with hexaminolevulinate hydrochloride? Can J Urol [Internet]. 2012 [cited 2019 Feb 18];19(3):6269–73. Available from.: http://www.ncbi.nlm.nih.gov/pubmed/22704312.

  27. Stenzl A, Burger M, Fradet Y, Mynderse LA, Soloway MS, Alfred Witjes J, et al. Hexaminolevulinate-guided fluorescence cystoscopy reduces recurrence in patients with non-muscle-invasive bladder cancer. Other study investigators. J Urol [Internet]. 2010 [cited 2019 Feb 12];184(5):1907–13. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4327891/pdf/nihms661771.pdf.

  28. Burger M, Grossman HB, Droller M, Schmidbauer J, Hermann G, Drăgoescu O, et al. Photodynamic diagnosis of non–muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol [Internet]. 2013 [cited 2019 Feb 18];64(5):846–54. Available from: https://www.sciencedirect.com/science/article/pii/S0302283813003539?via%3Dihub.

  29. Grossman HB, Gomella L, Fradet Y, Morales A, Presti J, Ritenour C, et al. A Phase III, Multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol [Internet]. 2007 [cited 2019 Feb 18];178(1):62–7. Available from: https://www.sciencedirect.com/science/article/pii/S0022534707005435.

  30. Lerner SP, Liu H, Wu M-F, Thomas YK, Witjes JA. Fluorescence and white light cystoscopy for detection of carcinoma in situ of the urinary bladder. Urol Oncol Semin Orig Investig [Internet]. 2012 [cited 2019 Feb 18];30(3):285–9. Available from: https://www.sciencedirect.com/science/article/pii/S1078143910002668?via%3Dihub.

  31. Witjes JA, Babjuk M, Gontero P, Jacqmin D, Karl A, Kruck S, et al. Clinical and cost effectiveness of hexaminolevulinate-guided blue light cystoscopy: evidence review and updated expert recommendations. Eur Urol [Internet]. 2014 [cited 2019 Feb 18];66(5):863–71. Available from: https://www.sciencedirect.com/science/article/pii/S0302283814006113?via%3Dihub.

  32. Daneshmand S, Patel S, Lotan Y, Pohar K, Trabulsi E, Woods M, et al. Efficacy and safety of blue light flexible cystoscopy with hexaminolevulinate in the surveillance of bladder cancer: a phase III, comparative, multicenter study. J Urol [Internet]. 2018 [cited 2019 Feb 18];199(5):1158–65. Available from: https://www.sciencedirect.com/science/article/pii/S0022534717780044.

  33. Steinberg G. Blue Light Cystoscopy Should be Used Routinely for Bladder Cancer Detection: Pro. J Urol [Internet]. 2016 [cited 2019 Feb 18];195(6):1652–3. Available from: https://www.sciencedirect.com/science/article/pii/S0022534716034583.

  34. Garfield SS, Gavaghan MB, Armstrong SO, Jones JS. The cost-effectiveness of blue light cystoscopy in bladder cancer detection: United States projections based on clinical data showing 4.5 years of follow-up after a single hexaminolevulinate hydrochloride instillation [Internet]. [cited 2019 Feb 12]. Available from: https://www.canjurol.com/html/free-articles/V20I2_04F_DrGarfield.pdf.

  35. Cauberg ECC, Mamoulakis C, de la Rosette JJMCH, de Reijke TM. Narrow-band imaging-assisted transurethral resection for non-muscle-invasive bladder cancer significantly reduces residual tumour rate. World J Urol [Internet]. 2011 [cited 2019 Feb 12];29(4):503–9. Available from: http://link.springer.com/10.1007/s00345-011-0659-2.

  36. Liu J-J, Droller MJ, Liao JC. New optical imaging technologies for bladder cancer: considerations and perspectives. J Urol [Internet]. 2012 [cited 2019 Feb 6];188(2):361–8. Available from: https://www.sciencedirect.com/science/article/pii/S0022534712034155.

  37. Zheng C, Lv Y, Zhong Q, Wang R, Jiang Q. Narrow-band imaging diagnosis of bladder cancer: systematic review and meta-analysis. BJU Int [Internet]. 2012 [cited 2019 Feb 12];110(11b):E680–7. Available from: http://doi.wiley.com/10.1111/j.1464-410X.2012.11500.x.

  38. Herr H, Donat M, Dalbagni G, Taylor J. Narrow-band imaging cystoscopy to evaluate bladder tumours-individual surgeon variability. 2009 [cited 2019 Feb 12.]; Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3137239/pdf/nihms297487.pdf.

  39. Naselli A, Introini C, Timossi L, Spina B, Fontana V, Pezzi R, et al. A randomized prospective trial to assess the impact of transurethral resection in narrow-band imaging modality on non–muscle-invasive bladder cancer recurrence. Eur Urol [Internet]. 2012 [cited 2019 Feb 6];61(5):908–13. Available from: https://www.sciencedirect.com/science/article/pii/S0302283812000206.

  40. Lokeshwar VB, Habuchi T, Grossman HB, Murphy WM, Hautmann SH, Hemstreet GP, et al. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology [Internet]. 2005 [cited 2019 Feb 12];66(6):35–63. Available from: https://www.sciencedirect.com/science/article/pii/S0090429505014925.

  41. Papanicolaou GN, Marshall VF. A new procedure for staining vaginal smears. Science [Internet]. 1942 [cited 2019 Feb 19];95(2469):438–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17842594.

  42. Wild PJ, Fuchs T, Stoehr R, Zimmermann D, Frigerio S, Padberg B, et al. Detection of urothelial bladder cancer cells in voided urine can be improved by a combination of cytology and standardized microsatellite analysis. Cancer Epidemiol Biomarkers Prev [Internet]. 2009 [cited 2019 Feb 19];18(6):1798–806. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19454613.

  43. Tomasini JM, Konety BR. Urinary markers/cytology: what and when should a urologist use. Urol Clin North Am [Internet]. 2013 [cited 2019 Feb 19];40(2):165–73. Available from: https://www.sciencedirect.com/science/article/pii/S0094014313000165?via%3Dihub.

  44. Têtu B. Diagnosis of urothelial carcinoma from urine. Mod Pathol [Internet]. 2009 [cited 2019 Feb 19];22(S2):S53–9. Available from: http://www.nature.com/articles/modpathol2008193.

  45. Villicana P, Whiting B, Goodison S, Rosser CJ. Urine-based assays for the detection of bladder cancer. Biomark Med [Internet]. 2009 [cited 2019 Feb 19];3(3):265. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20161673.

  46. Wiener HG, Vooijs GP, van’t Hof-Grootenboer B. Accuracy of urinary cytology in the diagnosis of primary and recurrent bladder cancer. Acta Cytol [Internet]. [cited 2019 Feb 19];37(2):163–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8465635.

  47. Raab SS, Slagel DD, Jensen CS, Teague MW, Savell VH, Ozkutlu D, et al. Low-grade transitional cell carcinoma of the urinary bladder: application of select cytologic criteria to improve diagnostic accuracy [corrected]. Mod Pathol [Internet]. 1996 [cited 2019 Feb 19];9(3):225–32. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8685219.

  48. Raitanen M-P, Aine R, Rintala E, Kallio J, Rajala P, Juusela H, et al. Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis. Eur Urol [Internet]. 2002 [cited 2019 Feb 12];41(3):284–9. Available from: https://www.sciencedirect.com/science/article/pii/S0302283802000064.

  49. Murphy WM. Current status of urinary cytology in the evaluation of bladder neoplasms. Hum Pathol [Internet]. 1990 [cited 2019 Feb 19];21(9):886–96. Available from: https://www.sciencedirect.com/science/article/pii/004681779090171Z?via%3Dihub.

  50. Konety BR, Metro MJ, Melham MF, Salup RR. Diagnostic value of voided urine and bladder barbotage cytology in detecting transitional cell carcinoma of the urinary tract. Urol Int [Internet]. 1999 [cited 2019 Feb 19];62(1):26–30. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10436427.

  51. Keesee SK, Briggman J V, Thill G, Wu YJ. Utilization of nuclear matrix proteins for cancer diagnosis. Crit Rev Eukaryot Gene Expr [Internet]. 1996 [cited 2019 Feb 19];6(2–3):189–214. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8855388.

  52. Reid-Nicholson MD, Ramalingam P, Adeagbo B, Cheng N, Peiper SC, Terris MK. The use of Urovysion™ fluorescence in situ hybridization in the diagnosis and surveillance of non-urothelial carcinoma of the bladder. Mod Pathol [Internet]. 2009 [cited 2019 Feb 19];22(1):119–27. Available from: http://www.nature.com/doifinder/10.1038/modpathol.2008.179.

  53. Ponsky LE, Sharma S, Pandrangi L, Kedia S, Nelson D, Agarwal A, et al. SCREENING and monitoring for bladder cancer: refining the use of NMP22. J Urol [Internet]. 2001 [cited 2019 Feb 19];166(1):75–8. Available from: https://www.sciencedirect.com/science/article/pii/S0022534705660806.

  54. Boman H, Hedelin H, Holmäng S. Four bladder tumor markers have a disappointingly low sensitivity for small size and low-grade recurrence. J Urol [Internet]. 2002 [cited 2019 Feb 19];167(1):80–3. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11743280.

  55. Witjes JA, van der Poel HG, van Balken MR, Debruyne FM, Schalken JA. Urinary NMP22 and karyometry in the diagnosis and follow-up of patients with superficial bladder cancer. Eur Urol [Internet]. 1998 [cited 2019 Feb 19];33(4):387–91. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9612682.

  56. Agarwal PK, Black PC, Kamat AM. Considerations on the use of diagnostic markers in management of patients with bladder cancer. World J Urol [Internet]. 2008 [cited 2019 Feb 12];26(1):39–44. Available from: http://link.springer.com/10.1007/s00345-007-0232-1

  57. Grossman HB, Soloway M, Messing E, Katz G, Stein B, Kassabian V, et al. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA [Internet]. 2006 [cited 2019 Feb 12];295(3):299. Available from: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.295.3.299.

  58. Konety BR. Molecular markers in bladder cancer: a critical appraisal. Urol Oncol Semin Orig Investig [Internet]. 2006 [cited 2019 Feb 19];24(4):326–37. Available from: https://www.sciencedirect.com/science/article/pii/S1078143905002875?via%3Dihub.

  59. van Rhijn BWG, van der Poel HG, van der Kwast TH. Urine markers for bladder cancer surveillance: a systematic review. Eur Urol [Internet]. 2005 [cited 2019 Feb 12];47(6):736–48. Available from: https://www.sciencedirect.com/science/article/pii/S030228380500148X.

  60. Pode D, Shapiro A, Wald M, Nativ O, Laufer M, Kaver I. Noninvasive detection of bladder cancer with the BTA stat test. J Urol [Internet]. 1999 [cited 2019 Feb 19];161(2):443–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9915422.

  61. Cajulis RS, Haines GK, Frias-Hidvegi D, McVary K, Bacus JW. Cytology, flow cytometry, image analysis, and interphase cytogenetics by fluorescence in situ hybridization in the diagnosis of transitional cell carcinoma in bladder washes: A comparative study. Diagn Cytopathol [Internet]. 1995 Oct 1 [cited 2019 Feb 19];13(3):214–23. Available from: http://doi.wiley.com/10.1002/dc.2840130307.

  62. Kipp BR, Karnes RJ, Brankley SM, Harwood AR, Pankratz VS, Sebo TJ, et al. Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization. J Urol [Internet]. 2005 [cited 2019 Feb 19];173(2):401–4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15643180.

  63. Schlomer BJ, Ho R, Sagalowsky A, Ashfaq R, Lotan Y. Prospective validation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. J Urol [Internet]. 2010 [cited 2019 Feb 19];183(1):62–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19913822.

  64. Skacel M, Fahmy M, Brainard JA, Pettay JD, Biscotti CV., Liou LS, et al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol [Internet]. 2003 [cited 2019 Feb 19];169(6):2101–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12771727.

  65. Hautmann S, Toma M, Gomez MFL, Friedrich MG, Jaekel T, Michl U, et al. Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison. Eur Urol [Internet]. 2004 [cited 2019 Feb 19];46(4):466–71. Available from: https://www.sciencedirect.com/science/article/pii/S0302283804002842.

  66. Mian C, Maier K, Comploj E, Lodde M, Berner L, Lusuardi L, et al. uCyt+/ImmunoCyt™ in the detection of recurrent urothelial carcinoma. Cancer [Internet]. 2006 [cited 2019 Feb 19];108(1):60–5. Available from: http://doi.wiley.com/10.1002/cncr.21712.

  67. Kiss B, Marcq G, Liao JC. Optical and cross-sectional imaging technologies for bladder cancer. Springer, Cham; 2018 [cited 2019 Feb 19]. p. 139–63. Available from: http://link.springer.com/10.1007/978-3-319-93339-9_7.

  68. Cowan NC, Crew JP. Imaging bladder cancer. Curr Opin Urol. 2010;20(5):409–13.

    Article  Google Scholar 

  69. Gray Sears CL, Ward JF, Sears ST, Puckett MF, Kane CJ, Amling CL. Prospective comparison of computerized tomography and excretory urography in the initial evaluation of asymptomatic microhematuria. J Urol [Internet]. 2002 [cited 2019 Feb 20];168(6):2457–60. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12441939.

  70. Vrtiska TJ, Hartman RP, Kofler JM, Bruesewitz MR, King BF, McCollough CH. Spatial resolution and radiation dose of a 64-MDCT scanner compared with published CT urography protocols. Am J Roentgenol [Internet]. 2009 [cited 2019 Feb 20];192(4):941–8. Available from: http://www.ajronline.org/doi/10.2214/AJR.07.2679.

  71. Jinzaki M, Kikuchi E, Akita H, Sugiura H, Shinmoto H, Oya M. Role of computed tomography urography in the clinical evaluation of upper tract urothelial carcinoma. Int J Urol [Internet]. 2016 [cited 2019 Feb 20];23(4):284–98. Available from: http://doi.wiley.com/10.1111/iju.13032.

  72. Silverman SG, Akbar SA, Mortele KJ, Tuncali K, Bhagwat JG, Seifter JL. Multi–detector row CT urography of normal urinary collecting system: furosemide versus saline as adjunct to contrast edium. Radiology [Internet]. 2006 Sep 1 [cited 2019 Feb 20];240(3):749–55. Available from: http://pubs.rsna.org/doi/10.1148/radiol.2403050233.

  73. Froemming A, Potretzke T, Takahashi N, Kim B. Upper tract urothelial cancer. Eur J Radiol [Internet]. 2018 [cited 2019 Feb 20];98:50–60. Available from: https://doi.org/10.1016/j.ejrad.2017.10.021.

  74. Hack K, Pinto PA, Gollub MJ. Targeted delayed scanning at CT urography: a worthwhile use of radiation? Radiology [Internet]. 2012 [cited 2019 Feb 20];265(1):143–50. Available from: http://pubs.rsna.org/doi/10.1148/radiol.12110548.

  75. CT and MRI Contrast and Kidney Function | UCSF Radiology [Internet]. 2015 [cited 2019 Feb 20]. Available from: https://radiology.ucsf.edu/blog/abdominal-imaging/ct-and-mri-contrast-and-kidney-function.

  76. Takahashi N, Glockner JF, Hartman RP, King BF, Leibovich BC, Stanley DW, et al. Gadolinium-enhanced magnetic resonance urography for upper urinary tract malignancy. J Urol [Internet]. 2010 [cited 2019 Feb 20];183(4):1330–6. Available from: http://www.jurology.com/doi/10.1016/j.juro.2009.12.031.

  77. Witjes JA, Kiemeney LALM, Verbeek ALM, Heijbroek RP, Debruyne FMJ, Group the DSECU. Random bladder biopsies and the risk of recurrent superficial bladder cancer: a prospective study in 1026 patients. World J Urol [Internet]. 1992 [cited 2019 Feb 19];10(4):231–4. Available from: http://link.springer.com/10.1007/BF00208916.

  78. Holzbeierlein JM, Smith JA. Surgical management of noninvasive bladder cancer (stages Ta/T1/CIS). Urol Clin North Am [Internet]. 2000 [cited 2019 Feb 19];27(1):15–24. Available from: https://www.sciencedirect.com/science/article/pii/S0094014305702305?via%3Dihub.

  79. Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, et al. Diagnosis and treatment of non-muscle-invasive bladder cancer: AUA/SUO guideline. J Urol. 2016;196(4):1021–9.

    Article  Google Scholar 

  80. Porten SP, Willis D, Kamat AM. Variant histology: role in management and prognosis of nonmuscle-invasive bladder cancer. Curr Opin Urol. 2014;24(5):517–23.

    Article  Google Scholar 

  81. Baris D, Karagas MR, Verrill C, Johnson A, Andrew AS, Marsit CJ, et al. A case–control study of smoking and bladder cancer risk: emergent patterns over time. JNCI J Natl Cancer Inst [Internet]. 2009 [cited 2019 Feb 18] ;101(22):1553–1561. Available from: https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/djp361.

  82. Dearing J. Disease-centred advice for patients with superficial transitional cell carcinoma of the bladder. Ann R Coll Surg Engl [Internet]. 2005 [cited 2019 Feb 18];87(2):85–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15826413.

  83. Fleshner N, Garland J, Moadel A, Herr H, Ostroff J, Trambert R, et al. Influence of smoking status on the disease-related outcomes of patients with tobacco-associated superficial transitional cell carcinoma of the bladder. Cancer [Internet]. 1999 [cited 2019 Feb 18];86(11):2337–45. Available from: http://doi.wiley.com/10.1002/%28SICI%291097-0142%2819991201%2986%3A11%3C2337%3A%3AAID-CNCR23%3E3.0.CO%3B2-6.

  84. Chen C-H, Shun C-T, Huang K-H, Huang C-Y, Tsai Y-C, Yu H-J, et al. Stopping smoking might reduce tumour recurrence in nonmuscle-invasive bladder cancer. BJU Int [Internet]. 2007 [cited 2019 Feb 6];100(2):281–6. Available from: http://doi.wiley.com/10.1111/j.1464-410X.2007.06873.x.

Download references

Author information

Authors and Affiliations

  1. Department of Urology, University of California Los Angeles Medical Center, Los Angeles, CA, USA

    Vishnukamal Golla & Karim Chamie

Authors
  1. Vishnukamal Golla
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karim Chamie
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vishnukamal Golla .

Editor information

Editors and Affiliations

  1. Department of Urology, University of Texas, MD Anderson Cancer Center, Houston, TX, USA

    Ashish M. Kamat

  2. Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada

    Peter C. Black

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Golla, V., Chamie, K. (2021). Oncological Monitoring of NonMuscle Invasive Bladder Cancer (NMIBC). In: Kamat, A.M., Black, P.C. (eds) Bladder Cancer. Springer, Cham. https://doi.org/10.1007/978-3-030-70646-3_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-70646-3_13

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-70645-6

  • Online ISBN: 978-3-030-70646-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation